Renal Effects after Pembrolizumab Treatment for Non-small Cell Lung Carcinoma

Immune checkpoint inhibitors (CPIs), including pembrolizumab, are becoming common oncological treatments. CPIs have been associated with a significant risk of developing immune-related adverse events (irAEs), such as nephritis and interstitial nephritis. However, the occurrence of glomerulonephritis...

Descripción completa

Detalles Bibliográficos
Autores principales: Oki, Rikako, Hirakawa, Yosuke, Kimura, Hitomi, Honda, Kenjiro, Hinata, Munetoshi, Abe, Hiroyuki, Domoto, Yukako, Tanaka, Goh, Nagase, Takahide, Nangaku, Masaomi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7184094/
https://www.ncbi.nlm.nih.gov/pubmed/31813918
http://dx.doi.org/10.2169/internalmedicine.3928-19
Descripción
Sumario:Immune checkpoint inhibitors (CPIs), including pembrolizumab, are becoming common oncological treatments. CPIs have been associated with a significant risk of developing immune-related adverse events (irAEs), such as nephritis and interstitial nephritis. However, the occurrence of glomerulonephritis has only rarely been reported. We herein present the case of a 75-year-old woman with non-small cell lung carcinoma (NSCLC) who developed proteinuria and microscopic hematuria during treatment with pembrolizumab. Renal biopsy revealed tubulointerstitial nephritis and IgA nephropathy. Considering that a urinalysis showed no abnormality before treatment, the condition might have been induced by pembrolizumab. In this report, we focus on the correct diagnosis and management of renal irAEs, which remain controversial.

Ejemplares similares